About Myovant Sciences (NYSE:MYOV)
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Industry, Sector and Symbol
Trailing P/E Ratio-7.58924699363779
Forward P/E Ratio-7.18
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book5.37
Return on Equity-90.86%
Return on Assets-74.94%
Myovant Sciences (NYSE:MYOV) Frequently Asked Questions
What is Myovant Sciences' stock symbol?
Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."
When will Myovant Sciences make its next earnings announcement?
Where is Myovant Sciences' stock going? Where will Myovant Sciences' stock price be in 2018?
4 analysts have issued 12-month price objectives for Myovant Sciences' shares. Their predictions range from $20.00 to $25.00. On average, they expect Myovant Sciences' stock price to reach $22.50 in the next twelve months. View Analyst Ratings for Myovant Sciences.
What are Wall Street analysts saying about Myovant Sciences stock?
Here are some recent quotes from research analysts about Myovant Sciences stock:
- 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (2/20/2018)
- 2. Cowen Inc analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017)
Who are some of Myovant Sciences' key competitors?
Some companies that are related to Myovant Sciences include Horizon Therapeutics (HPTX), Anika Therapeutics (ANIK), Apellis Pharmaceuticals (APLS), Vitae Pharmaceuticals (VTAE), Sinovac Biotech (SVA), ChemoCentryx (CCXI), 3SBio (SSRX), Syros Pharmaceuticals (SYRS), Kadmon (KDMN), Strongbridge Biopharma (SBBP), Vericel (VCEL), Synlogic (SYBX), Syndax Pharmaceuticals (SNDX), Catalyst Biosciences (CBIO), Kamada (KMDA), Mereo BioPharma Group (MPH), Fortress Biotech (FBIO) and KalVista Pharmaceuticals (KALV).
Who are Myovant Sciences' key executives?
Myovant Sciences' management team includes the folowing people:
- Lynn Seely M.D., Principal Executive Officer, Director (Age 58)
- Frank L. Karbe, Principal Financial, Accounting Officer (Age 49)
- Marianne L. Romeo, Head, Global Transactions & Risk Management (Age 49)
- Terrie Curran, Director (Age 48)
- Keith S. Manchester M.D., Director (Age 48)
- Vivek Ramaswamy, Director (Age 31)
- Mark Altmeyer, Independent Director (Age 56)
- Wayne S. DeVeydt, Independent Director (Age 47)
When did Myovant Sciences IPO?
(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.
Who owns Myovant Sciences stock?
Who sold Myovant Sciences stock? Who is selling Myovant Sciences stock?
Who bought Myovant Sciences stock? Who is buying Myovant Sciences stock?
How do I buy Myovant Sciences stock?
Shares of Myovant Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myovant Sciences' stock price today?
One share of Myovant Sciences stock can currently be purchased for approximately $14.87.
How big of a company is Myovant Sciences?
Myovant Sciences has a market capitalization of $905.69 million. The company earns $-83,440,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis. Myovant Sciences employs 36 workers across the globe.
How can I contact Myovant Sciences?
Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 203-318-9709 or via email at [email protected]
MarketBeat Community Rating for Myovant Sciences (MYOV)MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Myovant Sciences (NYSE:MYOV) Earnings History and Estimates Chart
Myovant Sciences (NYSE MYOV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/13/2018|| || || || || || || || |
Myovant Sciences (NYSE:MYOV) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-1.58 EPS
Dividend History for Myovant Sciences (NYSE:MYOV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Myovant Sciences (NYSE MYOV)
No insider trades for this company have been tracked by MarketBeat.com
Myovant Sciences (NYSE MYOV) News Headlines
Myovant Sciences (NYSE:MYOV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Myovant Sciences (NYSE:MYOV) Income Statement, Balance Sheet and Cash Flow Statement
Myovant Sciences (NYSE MYOV) Stock Chart for Tuesday, February, 20, 2018